Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsPharmaceutical Vardenafil
PharmaceuticalPharmaceuticalVasodilatorPDE5 inhibitor

Vardenafil

Also known as Levitra · Staxyn · Vardenafil hydrochloride

Vardenafil is a potent second-generation PDE5 inhibitor structurally similar to sildenafil but roughly an order of magnitude more potent on a molar basis, so effective doses are lower. It offers a similar on-demand profile for erectile dysfunction and is sometimes chosen when sildenafil is ineffective or poorly tolerated.

01 Overview

Vardenafil selectively inhibits PDE5 with high potency. Clinically its efficacy is comparable to sildenafil, with a similar onset (~30-60 minutes) and a half-life of about 4-5 hours. It carries a modest QT-prolongation signal, so it is avoided in those with QT risk or on QT-prolonging drugs, and an orally disintegrating formulation exists.

In PED use it occupies the same niche as sildenafil — on-demand erectile support and vasodilation — and is chosen by some users who respond poorly to sildenafil. The nitrate contraindication and alpha-blocker interaction apply, and the QT consideration is a point of difference from the other agents.

02 Mechanism

High-potency selective inhibition of PDE5, increasing cGMP and enhancing nitric-oxide-mediated cavernosal vasodilation.

03 Dosing

TierDoseRouteNotes
Low5 mgOralStarting dose in the elderly or on interacting drugs.
Erectile function10–20 mgOralTaken ~30-60 min before activity; 20 mg is the label ceiling.

04 Effects

EffectMagnitudeEvidence
Improved erectile functionEfficacy comparable to sildenafil in restoring erectile function.~70-80% responder rateClinical
High potency at low doseLower milligram doses achieve equivalent PDE5 inhibition.~10x molar potency vs sildenafilClinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Headache and flushingVasodilatory headache, flushing and nasal congestion.MildVery commonClinical
QT prolongationModest QT-interval prolongation, a distinguishing feature versus other PDE5 inhibitors.ModerateUncommonClinical
Nitrate interaction (severe hypotension)Additive, potentially fatal hypotension with nitrates or NO donors.Life-threateningRare but potentially fatalClinical

07 References

Vardenafil, a new PDE5 inhibitor, in men with erectile dysfunctionJ Urol, 2001
Levitra (vardenafil) FDA labelUS FDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.